NCT06765915View on ClinicalTrials.gov

Avapritinib Maintenance for AML With KIT Mutations

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2028

Conditions
AML, Adult
Interventions
DRUG

Avapritinib

After allo-HSCT, CBF-AML patients who have kit mutation would receive avapritinib for maintenance therapy.

Trial Locations (1)

Unknown

Ruijin Hospital of Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER